Table 3.

Cumulative average epoetin dosage and mortality HRs from standard (unweighted) regression models^a

U/wk	Primary Analysis		Secondary Analysis A		Secondary Analysis B
	HR	95% CI	HR	95% CI	HR	95% CI
<10,000	0.73	0.65 to 0.83	0.70	0.62 to 0.79	0.85	0.75 to 0.96
10,000 to <20,000	0.82	0.74 to 0.91	0.80	0.72 to 0.88	0.89	0.80 to 0.99
20,000 to <30,000 (reference group)	Reference		Reference		Reference
30,000 to <40,000	1.16	1.02 to 1.33	1.09	0.95 to 1.24	1.11	0.96 to 1.28
≥40,000	1.26	1.10 to 1.44	1.26	1.10 to 1.43	1.27	1.10 to 1.46

^aThe standard regression models include baseline covariates (age, race, gender, underlying cause of ESRD, geographic region, Charlson index score, cardiovascular and noncardiovascular comorbidities, baseline hematocrit, average intravenous iron administered, length of inpatient stays in the baseline, and average epoetin dosage and number of administrations at baseline) and time-varying covariates (previous month's hematocrit, iron treatment, and length of hospital stay).